
Preliminary research with the PET radiopharmaceutical 68Ga-NYM096 has demonstrated a 95.7 percent accuracy rate in patients with primary clear cell renal cell carcinoma (ccRCC) and a significantly higher mean SUVmax in the most active lesions in comparison to 18F-FDG.



























